SGLT2 억제제와 만성 콩팥병

키워드

참고문헌 (36)

1. Mather A, "Glucose handling by the kidney", Kidney Int Suppl, 120, pp.S1~S6 (2011)
2. Wright EM, "Biology of human sodium glucose transporters", Physiol Rev, 91, pp.733~794 (2011)
3. Zehra T, "Tubuloglomerular feedback synchronization in nephrovascular networks", J Am Soc Nephrol, 32, pp.1293~1304 (2021)
4. Tonneijck L, "Glomerular hyperfiltration in diabetes : mechanisms, clinical significance, and treatment", J Am Soc Nephrol, 28, pp.1023~1039 (2017)
5. Vallon V, "Targeting renal glucose reabsorption to treat hyperglycaemia : the pleiotropic effects of SGLT2inhibition", Diabetologia, 60, pp.215~225 (2017)
6. Cherney DZI, "Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin", Kidney Int, 93, pp.231~244 (2018)
7. Heerspink HJL, "Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes", Diabetes Obes Metab, 15, pp.853~862 (2013)
8. Cherney DZ, "The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus", Cardiovasc Diabetol, 13, pp.28~ (2014)
9. Mihai S, "Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome", J Immunol Res, 2018, pp.2180373~ (2018)
10. Dekkers CCJ, "Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers", Diabetes Obes Metab, 20, pp.1988~1993 (2018)
11. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
12. Cherney DZI, "Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease : an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial", Lancet Diabetes Endocrinol, 5, pp.610~621 (2017)
13. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
14. Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
15. Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy", N Engl J Med, 380, pp.2295~2306 (2019)
16. Heerspink HJL, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
17. Wheeler DC, "Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial", Lancet Diabetes Endocrinol, 9, pp.22~31 (2021)
18. The EMPA-KIDNEY Collaborative Group, "Empagliflozin in patients with chronic kidney disease", N Engl J Med, 388, pp.117~127 (2023)
19. Chertow GM, "Effects of dapagliflozin in stage 4 chronic kidney disease", J Am Soc Nephrol, 32, pp.2352~2361 (2021)
20. Cherney DZI, "Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease(DIAMOND) : a randomised, double-blind, crossover trial", Lancet Diabetes Endocrinol, 8, pp.582~593 (2020)
21. Wheeler DC, "A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy", Kidney Int, 100, pp.215~224 (2021)
22. EMPA-KIDNEY Collaborative Group, "Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease : secondary analyses of the EMPAKIDNEY trial", Lancet Diabetes Endocrinol, 12, pp.51~60 (2024)
23. Koshino A, "Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease : data from the DELIGHT trial", Cardiovasc Diabetol, 22, pp.330~ (2023)
24. Ishikawa N, "SGLT gene expression in primary lung cancers and their metastatic lesions", Jpn J Cancer Res, 92, pp.874~879 (2001)
25. Zhou J, "Sodium-glucose co-transporter-2(SGLT-2)inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK", mTOR pathway, 2020, pp.132, 110821~
26. Yamamoto L, "Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro", Diabetol Int, 12, pp.389~398 (2021)
27. Kaji K, "Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake", Int J Cancer, 142, pp.1712~1722 (2018)
28. Lega IC, "Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection : a population-based study of older women and men with diabetes", Diabetes Obes Metab, 21, pp.2394~2404 (2019)
29. Uitrakul S, "The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2inhibitors : a real-world observational study", Medicines(Basel), 9, pp.59~ (2022)
30. Thong KY, "Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment : the ABCD nationwide dapagliflozin audit", Prim Care Diabetes, 12, pp.45~50 (2018)
31. Blau JE, "Ketoacidosis associated with SGLT2 inhibitor treatment : analysis of FAERS data", Diabetes Metab Res Rev, 33, pp.e2924~ (2017)
32. Palmer BF, "Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy", Clin J Am Soc Nephrol, 16, pp.1284~1291 (2021)
33. Daniele G, "Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes", Diabetes Care, 39, pp.2036~2041 (2016)
34. Ryan PB, "Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus : a real-world meta-analysis of 4 observational databases(OBSERVE-4D)", Diabetes Obes Metab, 20, pp.2585~2597 (2018)
35. Neuen BL, "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2diabetes : a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 7, pp.845~854 (2019)
36. Yau K, "Prescribing SGLT2 inhibitors in patients with CKD : expanding indications and practical considerations", Kidney Int Rep, 7, pp.1463~1476 (2022)

관련 논문AI추천